Study S003419

Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03249506
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 25358
Start: 2016-05-12
Primary completion: 2017-11-01
Lead sponsor: Janssen Research & Development, LLC
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 Inhibitor (DPP-4); DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1); DRUG:Thiazolidinedione (TZD); DRUG:Sulfonylureas; DRUG:Insulin
Results posted: FALSE
Secondary identifiers: OTHER:RRA-17640

Registered primary outcomes

Incidence Rate of the Composite of All-cause Mortality (ACM) or Hospitalization for Heart Failure (HF) [approximately 3 years]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.